Related Experiment Videos
[Clinical examination of cefoperazone in pediatrics (author's transl)]
Insights
Cefoperazone (CPZ), a new cephalosporin antibiotic, showed a 75% efficacy rate in treating bacterial infections in children, including pneumonia and sepsis, with no observed side effects.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Antimicrobial Therapy
Background:
- Bacterial infections pose a significant threat to pediatric health.
- New antimicrobial agents are crucial for combating resistant pathogens.
- Cephalosporins are a widely used class of antibiotics.
Observation:
- Seventeen children with bacterial infections (pneumonia, bronchitis, tonsillitis, sepsis, meningitis) were treated with cefoperazone (CPZ).
- CPZ was administered intravenously at dosages ranging from 56 to 182 mg/kg/day in four divided doses.
- Treatment duration varied from 4 to 15 days.
Findings:
- Cefoperazone demonstrated an overall efficacy rate of 75.0% in the pediatric cohort.
- Clinical outcomes were rated as excellent in 3 cases, good in 9, and moderate in 3.
- No adverse side effects were reported during the study period.
Implications:
- Cefoperazone presents a promising therapeutic option for pediatric bacterial infections.
- The favorable efficacy and safety profile warrant further investigation.
- This study supports the potential role of CPZ in pediatric infectious disease management.
Abstract:
Clinical studies on cefoperazone (CPZ), a new cephalosporin, were carried out at our department. Seventeen children wih the following bacterial infections were treated with CPZ; pneumonia (7), bronchitis (6), tonsillitis (1), sepsis (2) and purulent meningitis (1). The dosage was 56 approximately 182 mg/kg/day, divided into 4 doses, and given intravenous injection. The duration of administration was from 4 to 15 days. Clinical results were excellent in 3 cases, good in 9 cases, moderate in 3 cases, poor in 1 case and uncertain in 1 case. The overall efficacy rate was 75.0%. No side effects were observed.